Genprex Secures Nasdaq Exception to Regain Compliance, Must Maintain $1.00 Bid Price Through December 7
GNPX is trading near its 52-week low of $5.945 (9.3% above the low).
Summary
Genprex received a Nasdaq exception to continue listing, contingent on maintaining a $1.00 minimum bid price daily through December 7, 2026, following its recent reverse stock split. The company remains at high risk of delisting if it fails to meet these terms.
Key Events · Legal and Risk Events · GNPX
-
Nasdaq Exception Granted
The Nasdaq Hearings Panel granted Genprex an exception to continue listing, requiring the company to demonstrate compliance with the $1.00 minimum bid price by July 29, 2026, and maintain it daily through December 7, 2026.
-
Strict Compliance Terms
The exception mandates a closing bid price at or above $1.00 every trading day until December 7, 2026, with the Panel retaining jurisdiction and the right to reconsider based on any adverse events.
-
Delisting Risk Remains High
If Genprex fails to maintain the bid price or any other listing requirement, Nasdaq could immediately suspend and delist the stock, with limited appeal rights under a new rule effective July 22, 2026.
-
Updated Risk Factors
The filing includes new risk factor language detailing the consequences of delisting, including reduced stock price, loss of market efficiencies, and impaired capital-raising ability.
Analysis · GNPX · Life Sciences
Genprex received a lifeline from the Nasdaq Hearings Panel, granting an exception to continue listing after the company's 1:22 reverse stock split. The exception requires the stock to close at or above $1.00 every trading day through December 7, 2026, with the Panel retaining jurisdiction. Failure to maintain compliance would trigger immediate delisting, which could severely impair the company's ability to raise capital and maintain investor confidence. The filing also highlights a new Nasdaq rule that could accelerate delisting if the market value of listed securities falls below $5 million for 30 consecutive business days, adding another layer of risk for this micro-cap biotech already under going-concern warnings.
At the time of this filing, GNPX was trading at $6.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1M. The 52-week trading range was $5.95 to $1,210.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.